Results 161 to 170 of about 166,681 (238)

Advances and Challenges in Micro/Nanocarrier‐Based Dermal Drug Delivery Systems for Acne Treatment

Advanced NanoBiomed Research, EarlyView.
Topical acne treatment faces challenges from skin barriers and complex causes. Micro/nanocarriers improve drug delivery by enhancing bioavailability, targeting, and duration. Combining carriers creates synergistic effects for systematic intervention.
Jintao Yang, Jie Chen, Yunmiao Ma, Qingwei Zhou, Yu Kong, Yingxiang Chen, Junjie Chi, Haihua Hu   +7 more
wiley   +1 more source

Selenium Nanomaterials for Wound Healing: Synergistic Strategies from Anti‐Infection to Tissue Regeneration

Advanced NanoBiomed Research, EarlyView.
Selenium nanoparticles (SeNPs) are emerging as multifunctional platforms for wound healing, integrating antimicrobial, anti‐inflammatory, and proregenerative activities. This review summarises key mechanisms and recent advances in SeNP‐enabled composite dressings, immunomodulatory nanocomposites, microenvironment‐responsive hydrogels, photothermal and ...
Yangxia Chen, Xiaoshuang Liang, Sirui Li, Shuoshan Li, Wei Liu, Yingping Lin, Siqi Li, Zehang Zhang, Judun Zheng, Tianfeng Chen, Rongyi Chen   +10 more
wiley   +1 more source

Efficacy and Safety of Minocycline-Containing Bismuth Quadruple Therapies Versus Standard First-Line Bismuth Quadruple Therapies for <i>Helicobacter pylori</i> Eradication: A Systematic Review and Meta-Analysis. [PDF]

Infect Dis Rep
Wazir HU, Khuram AM, Reza IMK, Ajmal H, Parveen H, Ahmed Z, Iftequar Y, Inam N, Sulaiman IM, Tummala N, Sajid HMM, Khan AZ, Shafaqat U.   +12 more
europepmc   +1 more source

Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy

Advanced NanoBiomed Research, EarlyView.
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley   +1 more source

Scalable Access to N‑Acylindole Linkages: Enabling the Synthesis of Antitrypanosomal Noncanonical Cyclic Peptides for Chagas Disease

Angewandte Chemie, EarlyView.
A gram‐scale supply of bulbiferamide A, which features a rare N‐acylindole linkage and possesses potent inhibitory activity against Trypanosoma cruzi epimastigotes (IC50 = 4.1 µM)—the causative parasite of Chagas disease—was successfully achieved. Moreover, the cyclization strategy developed in this study facilitated the synthesis of noncanonical ...
Jie Zhang, Hugh Nakamura
wiley   +2 more sources

Eradication rates of Helicobacter pylori regimens and predictors of treatment failure: A multicenter real-world study in Saudi Arabia. [PDF]

Saudi J Gastroenterol
Almalki F, Alotaibi AD, Almaghrabi M, AlSulaiman RS, Alsolami HA, Alelyani JM, Bafarag SM, Alsebaey A, Aldossari ML, Buhulaigah SH, Alamri TA, Alhafid IA, Alzahrani IM, Al-Abdulwahab AA, Alhassani RY, Azooni RS, Alghamdi DJ, Alqhtani SAM, Alamro SM, Albadrani AA, AlQahtani SY, Alsaiari RA, Alharbi LA, Alotaibi ME, Alhazmi A, Alereinan AA.   +25 more
europepmc   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice. [PDF]

Aliment Pharmacol Ther
Gisbert JP, Parra P, Nyssen OP.
europepmc   +1 more source